In March 2024, CMS issued a memo clarifying that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be added to Medicare Part D plans, including Medicare Advantage, for that specific use
Just because you can doesnt mean you should, said Dr
GLP-1 receptors are present on pancreatic ductal cells, and animal studies suggested potential proliferative effects
In this context, we note that the remarkable effects of GLP-1RAs in achieving weight loss may fail to be maintained over the long term once medications are stopped 247
Rotating at least one inch from your previous injection site maintains healthy tissue for optimal absorption
Still, this early study indicates GLP-1 medications therapeutic potential in ocular inflammatory disease